Table 1 Demographic, clinical and laboratory characteristics of HIV-infected patients included in the study and those positive for HLA-B*5701 allele
From: HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
Variable | Total | HLA-B*5701-positive | p |
|---|---|---|---|
N = 902 | n = 24 | ||
Sex, n (%) | |||
Male | 750 (83.1%) | 20 (83.3%) | |
Female | 152 (16.9%) | 4 (16.7%) | 0,62 |
Age (years) | |||
Median (IQR) | 29 (24–39) | 36 (23–45) | |
< 20 | 71 (7.9%) | 1 (4.2%) | 0,43 |
20–29 | 382 (42.4%) | 9 (37.5%) | 0,39 |
30–39 | 226 (26.2%) | 6 (25%) | 0,61 |
40–49 | 117 (12.9%) | 4 (16.7%) | 0,39 |
50–59 | 73 (8.1%) | 3 (12.5%) | 0,31 |
> 60 | 23 (2.5%) | 1 (4.2%) | 0,47 |
Race | |||
Afro-Colombian | 54 (6.0%) | 1 (4.2%) | 0,58 |
Caucasian | 50 (5.5%) | 2 (8.3%) | 0,39 |
Indigenous | 5 (0.6%) | 0 (0%) | 0,87 |
Mestizo | 793 (87.9%) | 21 (87.5%) | 0,57 |
Region of origin | |||
Andean | 259 (28.7%) | 4 (16,7%) | 0,14 |
North | 226 (25.1%) | 2 (8,3%) | 0,04 |
Central | 200 (22.2%) | 12 (50%) | 0,003 |
Western | 169 (18.7%) | 5 (20,8%) | 0,48 |
Eastern | 48 (5.3%) | 1 (4,2%) | 0,63 |
Time since HIV diagnosis (days) | |||
Median (IQR) | 36 (21–74) | 67 (28–429) | |
≤ 30 | 367 (40.7%) | 8 (33.3%) | 0,31 |
31–180 | 414 (45.9%) | 6 (25%) | 0,03 |
181–360 | 39 (4.3%) | 3 (12.5%) | 0,09 |
361–720 | 30 (3.3%) | 3 (12.5%) | 0,05 |
> 720 | 52 (5.8%) | 4 (16.7%) | 0,05 |
Baseline CD4 cell count (cells/mm3) | |||
Median (IQR) | 321 (177–504) | 450 (360–638) | |
< 200 | 257 (28.4%) | 2 (8.4%) | 0,02 |
200–499 | 419 (46.5%) | 11 (45.8%) | 0,56 |
≥ 500 | 226 (25.1%) | 11 (45.8%) | 0,02 |
Baseline HIV viral load (copies/mL) | |||
Median (IQR) | 44,332 (11206–156,278) | 9064 (2749–22,248) | |
< 40 | 14 (1.5%) | 2 (8.3%) | 0,06 |
40–1000 | 48 (5.3%) | 3 (12.5%) | 0,14 |
1001–10,000 | 145 (16.1%) | 9 (37.5%) | 0,01 |
10,001–100,000 | 391 (43.4%) | 8 (33.3%) | 0,22 |
> 100,000 | 304 (33.7%) | 2 (8.3%) | 0,004 |
CDC clinical stage at diagnosis | |||
A | 613 (67.9%) | 22 (91.7%) | 0,007 |
B | 141 (15.6%) | 0 (0%) | 0,02 |
C | 148 (16.4%) | 2 (8.3%) | 0,22 |